Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

The recently developed anti‐androgen enzalutamide also known as (MDV3100) has the advantage to prolong by 4.8 months the survival of castration resistant prostate cancer (CRPC) patients. However, the mechanisms behind the potential side effects involving the induction of the prostate cancer (PCa) ne...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Oncol
Main Authors: Dang, Qiang, Li, Lei, Xie, Hongjun, He, Dalin, Chen, Jiaqi, Song, Wenbing, Chang, Luke S., Chang, Hong-Chiang, Yeh, Shuyuan, Chang, Chawnshang
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2015
Assuntos:
Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528811/
https://ncbi.nlm.nih.gov/pubmed/25817444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.02.010
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares